(Q35597143)

English

High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B

scientific article published on January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

C-L Lin

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

S-L Tsai

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

T-H Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

R-N Chien

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

S-K Liao

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Y-F Liaw

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

152-161

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Comprehensive Analysis of CD8+-T-Cell Responses against Hepatitis C Virus Reveals Multiple Unpredicted Specificities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Human T-cell receptor variable gene segment families

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Hepatitis B virus immunopathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Genes of the T-cell antigen receptor in normal and malignant T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

12 July 2018

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Clinical trial of lamivudine in children with chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Characterization of T Cell Clones Specific to a Determinant of Hepatitis B Virus Core and e Antigens in Chronic Type B Hepatitis: Implication for a T Cell Mechanism of HBV Immunopathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1774356

26 September 2018

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of rearranged T cell receptor (TCR) V beta transcripts in livers of primary biliary cirrhosis: preferential V beta usage suggests antigen-driven selection

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://pubmed.ncbi.nlm.nih.gov/15591521

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.2003.032920

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35597143&oldid=1720676923"